Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
7 927,75 pts
-1.89%


Last updated : 20/11/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

GENFIT: FDA Grants Key Designation to Its Candidate for Cirrhosis

GENFIT announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to G1090N (nitazoxanide), its experimental candidate for the treatment of acute decompensation in cirrhosis. This recognition of therapeutic potential paves the way for progression to phase 2 clinical trials.


GENFIT: FDA Grants Key Designation to Its Candidate for Cirrhosis

FDA Approval for Orphan Drug Designation

The FDA has granted ODD to G1090N, GENFIT's most advanced program in the segment of acute decompensation in cirrhosis (ACLF). This designation recognizes the potential of the active substance to treat this rare disease characterized by rapid deterioration in patient condition, systemic inflammation, and high short-term mortality. The ODD follows recent phase 1 results demonstrating a favorable safety and tolerability profile in healthy volunteers, as well as data regarding anti-inflammatory activity observed in ex vivo models.

Regulatory and Financial Advantages of ODD

The ODD designation provides GENFIT with FDA regulatory support, certain administrative fee reductions, and eligibility for seven years of market exclusivity in the United States for this indication if approved. These benefits create a solid foundation for advancing the program towards the initiation of a phase 2 clinical trial, scheduled for the second half of 2026.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 36,4 millions d'euros
  • Quarterly revenue: 36,4 millions d'euros
  • Revenue growth: -7,1 %
Guidance from the release
  • « conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
  • Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
  • Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
  • Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
  • Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
  • Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
  • Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours